Related Experiment Video
Updated: Jun 25, 2025
08:38
Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
16.9K
Tacrolimus Treatment for TAFRO Syndrome
Taiichiro Shirai1,2,3, Shinya Ichikawa1, Jun Saegusa1
1Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Biomedicines
|May 25, 2024
Summary
TAFRO syndrome, a severe inflammatory disorder, may be effectively treated with tacrolimus and glucocorticoids. This combination shows promise as an initial therapy and a way to reduce glucocorticoid use.
Area of Science:
- Hematology
- Immunology
- Internal Medicine
Background:
- TAFRO syndrome is an acute, systemic inflammatory disorder with high mortality.
- Its lymph node pathology resembles idiopathic multicentric Castleman disease (iMCD), but TAFRO syndrome presents with a more aggressive clinical course.
- The pathogenesis of TAFRO syndrome is poorly understood, and optimal treatment strategies remain elusive.
Keywords:
TAFRO syndromecalcineurin inhibitoriMCD-TAFROidiopathic multicentric Castleman disease (iMCD)tacrolimusMore Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131